Big Data IV: breakthroughs in drug discovery with AI
Big Data IV: breakthroughs in drug discovery with AI takes place on 9 February 2027 at SCI HQ, London. It is organised by Society of Chemical Industry, and B2DB lists 7 speakers and 8 sessions announced so far.
Big Data is the process of analysing high volume, high velocity data by advanced computational methods that produce actionable knowledge. A system that suggests actions to a user is one definition of Artificial Intelligence (AI). Since the last meeting in February 2024, much has happened in chemical industries with whole companies spawned around the use of AI to achieve breakthroughs. In the fourth event in this series, presenters will update on what is working for chemistry in addressing two pharmaceutical industry problems, well validated biological targets and quality chemical starting matter (hits) to optimise into drugs, and what is not. The one-day conference is organised by SCI's Fine Chemicals group and is intended as a high-level overview for chemists and decision makers.
Key facts
| Dates | 9 February 2027 (upcoming) |
|---|---|
| Venue | SCI HQ, London, United Kingdom |
| Organiser | Society of Chemical Industry |
| Speakers | 7 |
| Sessions | 8 |
| Official site | soci.org/events/fine-chemicals-group/2027/big-data-iv-breakthroughs-in-drug-discovery-with-ai |
Keynote speakers
- Tudor Oprea Drug Hunter
Speakers (7)
Compiled from the published agenda; speakers can claim and verify their own entry.
- Tudor Oprea Drug Hunter
- Anne Mai Wassermann Johnson & Johnson
- Chris Radoux Recursion
- Ed Griffen MedChemica Ltd / OpenBind Consortium
- James Lumley GSK
- Kathryn Giblin AstraZeneca
- Robin Roehm Apheris
Agenda (8 sessions)
Day 1 — Tuesday 9 February 2027
- Plenary speaker 10:00 — Tudor Oprea
- Generating, Scoring, Learning: Lessons from applying AI to real drug projects 10:40 — Kathryn Giblin
- The best model for your targets isn't trained on your data alone 11:40 — Robin Roehm
- Using AI to accelerate better science - learnings from massive scale FBDD and SBDD programs ASAP and OpenBind 12:20 — Ed Griffen
- From cofolding to compound: Turning predicted structures into projects worth pursuing? 14:00
- Presentation by Chris Radoux (Recursion) 14:40 — Chris Radoux
- Presentation by James Lumley (GSK) 15:40 — James Lumley
- From AI models to AI-native discovery: Turning data, models and scientific workflows into better decisions 16:30 — Anne Mai Wassermann
Organisers, sponsors and partners
Organiser (1)
Exhibitor (1)
Source: the published agenda. See how B2DB compiles its records.